Multivariate analysis of 36-month OS in a Cox model
Variable . | No. evaluable . | Hazard ratio of OS (95% CI)* . | P (overall) contrast† . |
|---|---|---|---|
| Transplantation group (main study variable) | |||
| Standard myeloablative conditioning‡ | 621 | (1) | |
| Reduced-intensity conditioning | 215 | 0.97 (0.76-1.25) | .82 |
| Patient age | |||
| 50 y or younger‡ | 508 | (1) | |
| Older than 50 y | 326 | 1.3 (1.05-1.6) | .02 |
| Disease group | (.02) | ||
| Secondary acute leukemia‡ | 463 | (1) | |
| Myelodysplasia | 276 | 0.72 (0.57-0.92) | .007 |
| Response to AML-type chemotherapy | (< .001) | ||
| First complete remission‡ | 276 | (1) | |
| Untreated | 241 | 1.3 (1.02-1.8) | .04 |
| Treated, but not in CR1 | 234 | 1.8 (1.4-2.4) | < .001 |
| Cytogenetics§ | (.045) | ||
| Non-poor risk‡ | 122 | (1) | |
| Poor-risk | 188 | 1.1 (0.8-1.5) | .47 |
Variable . | No. evaluable . | Hazard ratio of OS (95% CI)* . | P (overall) contrast† . |
|---|---|---|---|
| Transplantation group (main study variable) | |||
| Standard myeloablative conditioning‡ | 621 | (1) | |
| Reduced-intensity conditioning | 215 | 0.97 (0.76-1.25) | .82 |
| Patient age | |||
| 50 y or younger‡ | 508 | (1) | |
| Older than 50 y | 326 | 1.3 (1.05-1.6) | .02 |
| Disease group | (.02) | ||
| Secondary acute leukemia‡ | 463 | (1) | |
| Myelodysplasia | 276 | 0.72 (0.57-0.92) | .007 |
| Response to AML-type chemotherapy | (< .001) | ||
| First complete remission‡ | 276 | (1) | |
| Untreated | 241 | 1.3 (1.02-1.8) | .04 |
| Treated, but not in CR1 | 234 | 1.8 (1.4-2.4) | < .001 |
| Cytogenetics§ | (.045) | ||
| Non-poor risk‡ | 122 | (1) | |
| Poor-risk | 188 | 1.1 (0.8-1.5) | .47 |
A hazard ratio less than 1.0 indicates that the variable leads to an increase of OS, while a value above 1.0 indicates that it leads to a reduction of OS.
Some risk factors in the Cox model contain a category for “unknown” to avoid loss of information; the overall P value between brackets denotes the P value of the complete risk factor; the individual P values denote the P values of the given contrasts to the reference category. For clarity, the “unknown” categories as well as the nonsignificant risk factors have been omitted from the table.
Reference group.
See “Patient and transplantation characteristics and definitions” for details.